Mobidiag Ltd, a Finnish molecular diagnostics company, today announced the CE-IVD marking of Amplidiag® CarbaR+MCR, a molecular test allowing detection of the main carbapenemase-producing organisms and colistin resistance markers in one single test.
Antimicrobial resistance is currently one of the biggest threats to global health. Mobidiag has been developing innovative diagnostic tools based on its proprietary technologies and patents covering screening method and related kits for carbapenemase genes responsible for carbapenem resistance in bacteria. The new Amplidiag® CarbaR+MCR test, along with existing Amplidiag® CarbaR+VRE, allow patient screening for multidrug resistant organisms to prevent their spreading in hospital environment.
“By obtaining the CE-IVD marking, the Amplidiag CarbaR+MCR test complement the currently available carbapenemases and resistances panel strengthening our commitment towards the fight against antibiotic resistance. Indeed Mobidiag has been using its expertise in the detection of gastrointestinal infections to combat multi-drug resistant organisms, a key application in our global strategy” said Tuomas Tenkanen, CEO at Mobidiag.
Amplidiag® CarbaR+MCR test is now available directly through Mobidiag and local distributors. For more information, visit our product page.
About Amplidiag® CarbaR+MCR (CE-IVD)
Amplidiag®
CarbaR+MCR is a qualitative multiplex PCR test allowing cost-effective
and fast analysis of the most common carbapenemase-producing organisms
and colistin resistance markers. The complete panel includes the
detection of the following genes: KPC, NDM, VIM, IMP, OXA-48, OXA-181, Acinobacter
OXA, MCR and GES. These bacteria may cause multiple antibiotics to
perform inefficiently, which in turn can lead to serious infections,
particularly in healthcare settings. This multiplex PCR test gives
results within a few hours directly from stool samples, rectal swabs or
pure culture as opposed to days with current culture-based screening
methods.
About Amplidiag® (CE-IVD)
Amplidiag
are multiplex tests for the detection of gastrointestinal infections.
They allow panel screening of the most relevant gastrointestinal
pathogens. Based on well-established real-time PCR technology, they
ensure optimal performance, suitability for high-volume screening use
and cost-effectiveness in mid-sized to large laboratory settings. In
addition, Mobidiag allows process automation from sample extraction to
PCR set-up with the Amplidiag Easy system.
Learn
more about Amplidiag.
About Mobidiag Ltd.
Established in 2000, Mobidiag develops
and commercializes innovative solutions to advance the diagnosis of
infectious diseases and serves the European clinical diagnostics market
since 2008. Mobidiag is headquartered in Espoo, Finland, with an R&D
center in France and subsidiaries in UK and Sweden.
Combining
Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive line
of products for fast, reliable and cost-efficient diagnostics for
infectious diseases and antibiotic resistances. Mobidiag is able to
cover all laboratories requirements no matter their size, throughput and
centralized/ decentralized organization
To learn more, visit mobidiag.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180418005977/en/
Mobidiag
Dorothee Allard, +33 1 55 25 17 13
marketing@mobidiag.com
Permalink: http://www.businesswire.com/news/home/20180418005977/en
